Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Press Releases
Palatin Technologies, Inc.  
February 6, 2025

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Last Patient / Last Visit CompletedTopline Data Readout Expected Later This Quarter

logo salamanca press

Salamanca Press

Local & Social